What Is Beckwith-Wiedemann Syndrome?

Beckwith-Wiedemann syndrome (BWS) is a rare genetic overgrowth condition present from birth, caused by disrupted gene regulation on chromosome 11p15.5. It affects roughly one in every 10,000 to 13,000 newborns, though the true number is probably higher because milder cases go undiagnosed. The hallmark features include an unusually large tongue, abdominal wall defects, low blood sugar in the newborn period, and a heightened risk of childhood cancers. What makes BWS especially complex is that its severity varies enormously from person to person, and that variation traces back to which specific molecular change is involved.

What Goes Wrong at the Genetic Level

BWS is not caused by a single gene mutation in the traditional sense. Instead, it stems from disruptions in genomic imprinting, a process where certain genes are normally silenced depending on whether they were inherited from the mother or the father. The genes involved sit in two neighboring regulatory regions on chromosome 11p15.5, often called imprinting center 1 (IC1) and imprinting center 2 (IC2). IC1 governs the growth-promoting gene IGF2 and the growth-restraining gene H19. IC2 governs CDKN1C, a gene that normally acts as a brake on cell growth. When imprinting goes awry, the balance tips toward too much growth signaling and not enough restraint.

The most common molecular finding, accounting for roughly half of all cases, is a loss of methylation at IC2 on the maternal chromosome. This reduces expression of the growth-suppressing gene CDKN1C, allowing cells to proliferate more freely. A deletion within IC2 on the maternal chromosome has been linked to lower CDKN1C expression in affected family members, confirming the importance of that regulatory region.¹

About 20 percent of cases involve paternal uniparental disomy (UPD), where a child inherits two copies of part of chromosome 11 from the father and none from the mother. This doubles the dose of IGF2 while losing the maternal copy of CDKN1C. These cases are almost always mosaic, meaning the abnormality is present in some cells but not others, which partly explains the wide spectrum of severity.² A smaller fraction of cases involve gain of methylation at IC1, which leads to overexpression of IGF2 on the maternal allele. Microdeletions in the IC1 region that remove binding sites for the insulator protein CTCF have been identified in families with BWS and Wilms tumor, demonstrating how even small structural changes can derail imprinting.³ Point mutations in CDKN1C itself account for a smaller percentage and are the main subtype that follows a clear inherited pattern.

Why the Molecular Subtype Matters So Much

A 2016 study of a large cohort found that each molecular subtype produces a recognizable clinical profile, though with overlap. Babies with IC1 gain-of-methylation almost always showed macrosomia (being born significantly larger than expected). Those with IC2 loss-of-methylation tended to show their overgrowth after birth rather than at birth, and were more likely to have exomphalos, a type of abdominal wall defect where organs protrude through the navel. Patients with paternal UPD more often had hemihyperplasia, where one side of the body grows larger than the other, and were less likely to have macroglossia. Ear anomalies and birthmarks called nevus flammeus tracked with the IC2/CDKN1C group.⁴

The distinction carries real consequences for tumor surveillance, which is covered in detail below. It also matters for genetic counseling: IC2 loss-of-methylation is typically sporadic with a very low recurrence risk in future pregnancies, while CDKN1C mutations can be inherited from a parent who carries the mutation on their maternal allele. Knowing the subtype helps families plan and helps clinicians tailor follow-up.

Cancer Risk and Screening

About 8 percent of children across the BWS spectrum develop an embryonal tumor. The most common is Wilms tumor, making up roughly half of all tumors, followed by hepatoblastoma at around 14 percent, neuroblastoma at about 10 percent, rhabdomyosarcoma at 5 percent, and adrenal carcinoma at 3 percent. The risk is highest in the first two years of life and declines progressively before puberty, eventually approaching that of the general population.⁵

Crucially, tumor risk is not evenly distributed across subtypes. Wilms tumor is strongly associated with IC1 gain-of-methylation and paternal UPD but has never been observed in patients whose only finding is IC2 loss-of-methylation. Hepatoblastoma occurred exclusively in UPD cases in the large genotype-phenotype study. Overall cancer risk was very high in the IC1 group, intermediate in UPD, and lowest in the IC2/CDKN1C group.⁶

Standard screening involves regular abdominal ultrasounds to look for kidney and liver tumors. The 2018 international consensus statement addressed whether measuring serum alpha-fetoprotein (AFP) alongside ultrasound would improve detection of hepatoblastoma. Though AFP is secreted by most hepatoblastomas, interpreting AFP levels in infants is tricky because levels are naturally high and variable in the first months of life. Babies with BWS may have higher AFP levels than healthy controls even without any tumor. Weighing the stress of repeated blood draws against the uncertain benefit, the consensus group voted against recommending routine AFP screening.⁷

Neonatal Hypoglycemia and Hyperinsulinism

Low blood sugar in the newborn period is one of the most immediate concerns in BWS. Most cases are mild and resolve within days with standard feeding management. A smaller proportion of babies, however, develop persistent hyperinsulinism, where the pancreas continues to secrete too much insulin despite low blood sugar. Research has linked this to defective potassium channels in the insulin-producing cells of the pancreas. In at least one documented case with mosaic paternal UPD, the channel protein SUR1 was found trapped inside cells rather than reaching the cell surface where it normally functions, effectively making the off-switch for insulin secretion nonfunctional.⁸

The molecular subtype also predicts how severe the hyperinsulinism will be and whether it responds to medication. Diazoxide, the first-line drug, works by opening potassium channels in the pancreas. A recent study found that patients with paternal UPD were far less likely to respond to diazoxide compared to those with IC2 loss-of-methylation. Among patients who had UPD combined with loss of heterozygosity in the potassium channel genes, none responded to diazoxide, and all required pancreatectomy (surgical removal of part of the pancreas).⁹ Pancreatectomy controls the hypoglycemia but can lead to diabetes later in life, a trade-off that adults with BWS sometimes contend with.

Managing Macroglossia

An enlarged tongue is one of the most visible features of BWS and occurs in the majority of affected children. It can interfere with breathing, feeding, speech development, and the alignment of teeth and jaw bones. When the tongue protrusion is severe or causes airway obstruction, tongue reduction surgery (partial glossectomy) becomes an option.¹⁰

Research over the past decade has shifted the conversation toward earlier surgery. A study of children who underwent tongue reduction found that those with severe obstructive sleep apnea saw their obstruction scores drop significantly after surgery, from an average of about 31 events per hour to 10, and their lowest overnight oxygen levels improved. These benefits applied equally to infants who had surgery before 12 months of age, and only one patient in the cohort needed a second procedure.¹¹ A systematic review confirmed improvements in speech intelligibility, tongue mobility, and breathing outcomes, with feeding and drooling also getting better across both early and later surgical groups. Dental and skeletal alignment improvements were less consistent.¹²

Not every child with macroglossia needs surgery. Some have only mild enlargement that does not obstruct breathing or significantly affect feeding. The decision is clinical, weighing airway safety, speech development, and how the tongue relates to the jaw and teeth over time.

Leg Length Discrepancy and Lateralized Overgrowth

Many children with BWS, particularly those with paternal UPD, develop hemihyperplasia, where one side of the body grows faster than the other. The most functionally significant consequence is a leg length discrepancy, which can affect posture, gait, and cause back pain if left unaddressed. A longitudinal study of over 100 patients with lateralized overgrowth found that the discrepancy averaged about 11 millimeters at diagnosis and grew to about 17 millimeters at the last visit. Among BWS patients specifically, those with paternal UPD had more severe discrepancies and faster progression.¹³

When the difference becomes clinically meaningful (generally above 2 centimeters), treatment options include guided growth, a minimally invasive orthopedic procedure that temporarily slows growth on the longer leg by placing small plates near the growth plates of the knee. In a case series of 22 BWS patients treated this way, half achieved equal leg lengths after an average follow-up of nearly 8 years. Most patients needed multiple procedures as growth continued. Serious complications were uncommon, though some patients developed minor alignment issues that needed correction.¹⁴

The Diagnostic Challenge of Mosaicism

Because many BWS-causing changes, especially paternal UPD, arise after fertilization rather than being present from the first cell, the abnormality often exists in only a fraction of cells. This mosaicism means a blood test can come back negative even in a child who clearly has BWS. A study that compared diagnostic rates between blood-only testing and blood-plus-tissue testing found that blood alone identified a molecular cause in about 24 percent of cases, while adding tissue samples (from skin, the pancreas, or tumor tissue) raised the yield to 57 percent. Among the additionally diagnosed patients, 14 had negative blood results but positive tissue results.¹⁵

This has practical implications. A child with features strongly suggestive of BWS should not be ruled out based on a single negative blood test. The international consensus statement introduced the broader term “Beckwith-Wiedemann spectrum” (BWSp) partly to capture individuals who have some clinical features with or without a confirmed molecular finding.¹⁶ When clinical suspicion is high, testing additional tissue types or using more sensitive molecular techniques can clinch the diagnosis and guide appropriate tumor surveillance.

A Link to Assisted Reproduction

Several studies have found a higher-than-expected proportion of BWS cases among children conceived through in vitro fertilization (IVF) and related assisted reproductive technologies (ART). A case-control study found that IVF-conceived children had roughly 18 times greater odds of having BWS compared to naturally conceived children, though the researchers cautioned that the confidence interval around that estimate was very wide.¹⁷ A separate study examining ART-conceived children with BWS found that five out of six had abnormal methylation at the IC2 region, consistent with an epigenetic disturbance rather than a genetic mutation.¹⁸

The working theory is that laboratory culture conditions or the hormonal stimulation involved in ART may interfere with normal methylation imprinting during the earliest stages of embryo development. It is worth keeping perspective, though: BWS remains rare even among ART-conceived children, and the absolute risk is still very small. The finding has not led to changes in ART clinical practice but has contributed to broader scientific interest in whether assisted reproduction affects imprinting at other genomic regions.

Cognitive and Emotional Development

Parents often worry about whether BWS affects their child’s intelligence. The reassuring news is that most children with BWS perform within the normal range on cognitive tests. A study of children and adolescents found adequate performance overall, though with a pattern of somewhat greater difficulty with language tasks compared to visual-spatial processing. Reading speed and mental calculation tended to be slower.¹⁹

The more noteworthy findings are on the emotional side. Children with BWS showed heightened anxiety, lower self-esteem, social withdrawal, and a tendency to suppress outward expressions of frustration. These traits were not linked to cognitive ability or to the severity of the clinical presentation. The researchers suggested these patterns may reflect the emotional toll of growing up with a visible difference and the stress of repeated medical procedures rather than a direct neurological effect of the syndrome. Interestingly, the same children showed strengths in social perception, possibly because heightened awareness of how others see them sharpens their ability to read social cues.²⁰

An exploratory study of preschool-age children found that about a quarter scored in the at-risk range for social withdrawal, and nearly half showed at-risk scores for social development. Older preschoolers tended to have more difficulties than younger ones, suggesting these challenges may compound over time as social expectations increase.²¹ Taken together, the evidence points toward proactive psychological support being just as important as the more visible medical interventions.

What Happens in Adulthood

BWS is often framed as a childhood condition, partly because the tumor risk drops off before puberty and the most intensive medical management happens early. But a study tracking adults with BWS paints a more nuanced picture. About 44 percent of adults had tall final stature. Surgery for BWS-related features was needed in 85 percent of the cohort at some point during their lives. Several adults carried lasting consequences of childhood issues: speech and swallowing difficulties from macroglossia (even after surgical correction), painful scoliosis from lateralized overgrowth, recurrent kidney stones, infertility in men likely related to undescended testes, and diabetes from pancreatectomy performed for hyperinsulinism.²²

Fertility is possible. In that same study, four adults had healthy children, three conceived naturally and one through ART. Severe intellectual disability was uncommon and, when present, appeared to be a consequence of neonatal complications like asphyxia rather than a direct effect of BWS itself. The overall message is that BWS does not simply resolve after childhood; it transitions into a set of adult health concerns that benefit from coordinated follow-up, ideally with clinicians who understand the syndrome’s history in each patient.

Silver-Russell Syndrome as the Mirror Image

One of the more striking things about BWS is that it has a molecular opposite. Silver-Russell syndrome (SRS) involves undergrowth rather than overgrowth, with features like low birth weight, short stature, and a small, triangular face. The two conditions arise from changes at the same chromosomal region, 11p15.5, but with opposite effects on gene expression. Where BWS involves too much activity of the growth-promoting gene IGF2 or too little activity of the growth-restraining CDKN1C, SRS involves the reverse pattern.²³ Specifically, IC1 gain-of-methylation is a hallmark of some BWS cases, while IC1 loss-of-methylation is the most common epigenetic finding in SRS. IC2 involvement also tends to produce opposite phenotypes in the two syndromes.²⁴

This relationship is more than a curiosity. It provides a natural experiment for understanding how imprinted genes regulate growth. It also creates practical overlap in genetic testing, since the same laboratory workup at the 11p15 region can diagnose both conditions. Prenatal testing for BWS and SRS has been performed in multiple centers, with molecular abnormalities on 11p15.5 detectable in over 70 percent of BWS cases.²⁵ The shared genetic territory means families dealing with either condition often benefit from the same specialists and the same advances in understanding imprinting biology.